



Fact Sheet

Respiratory





SCOPE is an **independent, global CRO** with proven expertise in **respiratory indications** across clinical **phases I–IV**. Our experience spans paediatric trials, orphan drugs, medical devices, non-interventional, and post-authorisation studies. Close collaborations with leading investigators and KOLs worldwide allow us to **deliver high-quality**, tailored solutions for your development programmes.

Proven Experience that Delivers

Our expertise ensures reliable study planning, engaged sites, effective recruitment, and minimised trial risks – saving time and protecting your investment.



37 / Completed Respiratory Studies

1,300 / Qualified Sites

24,000 / Subjects



Global Reach & Experience

Since 2000, SCOPE has conducted over 300 studies with 88,000 subjects, including 37 recent respiratory trials. With 11 offices across Europe and a global partner network, we operate wherever clinical trial services are required.

Highlights:

- Phase I–IV respiratory trials, from single protocols to full development programmes
- Extensive experience across multiple respiratory disease states

Your CRO of Choice for _____ Respiratory



Why Respiratory Trials Need SCOPE

With the rising incidence of respiratory diseases and allergies, specialised trial expertise is essential. SCOPE consistently meets enrolment targets on time and on budget, supporting custom recruitment strategies.

Key Advantages

Efficient patient recruitment & site engagement

Tailored approaches for each clinical stage

Rapid feasibility assessments & consulting

Large international investigator networks

more ...



Trial Capabilities & Study Design

We manage a wide range of study types, including Phase I–III trials, post-authorisation studies, adaptive designs, and complex device/diagnostic combination studies.

Expertise includes:

- Device trials for Asthma, COPD, ARDS, Hypercapnic Respiratory Failure, RSV in children
- Biostatistical support for randomisation, stratification, non-inferiority, adaptive designs
- Post-marketing & pharmacoeconomic assessments



What Sets SCOPE Apart

Our team of experienced project managers, CRAs, data managers, biostatisticians, and medical staff are fully versed in respiratory protocols. Strong investigator and KOL relationships enable rapid feasibility, consulting, and decision-making.

Differentiators:

- Dedicated respiratory/pulmonology expertise
- Low employee turnover, ensuring consistency and continuity
- Proven track record in achieving enrolment and regulatory objectives
- Tailored strategies for patient recruitment, site management, and trial execution



Therapeutic Areas

Asthma (mild, moderate, severe, paediatrics)

COPD

COVID-19

Asthma/COPD-Overlapping Syndrome (ACOS)

Development of a dry-powder inhaler

CAP (Community-Acquired Pneumonia)

PROVEN RESULTS IN RESPIRATORY



“Reliable delivery in complex respiratory trials”

SCOPE combined strong respiratory expertise with pragmatic study management. Recruitment targets were met despite complex protocols and demanding timelines.

Clinical Development Lead, Pharmaceutical Company

SCOPE International AG

Konrad-Zuse-Ring 18
68163 Mannheim, Germany
Phone +49 621 42939 0

For further information please contact
SCOPE's Business Development Team:
contact@scope-international.com

www.scope-international.com

Follow us on

